The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Salermide, a Sirtuin inhibitor with a strong cancer-specific proapoptotic effect
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Development and validation of a genetic algorithm for flexible docking 1 1Edited by F. E. Cohen
Jones, G., Willett, P., Glen, R. C., Leach, A. R., & Taylor, R. (1997) · Journal of Molecular Biology · doi:10.1006/jmbi.1996.0897 · Cited by 6,763
Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan
Howitz, K. T., Bitterman, K. J., Cohen, H. Y., Lamming, D. W., Lavu, S., Wood, J. G., Zipkin, R. E., Chung, P., Kisielewski, A., Zhang, L.-L., et al. (2003) · Nature · doi:10.1038/nature01960 · Cited by 3,796
hSIR2SIRT1 Functions as an NAD-Dependent p53 Deacetylase
Vaziri, H., Dessain, S. K., Eaton, E. N., Imai, S.-I., Frye, R. A., Pandita, T. K., Guarente, L., & Weinberg, R. A. (2001) · Cell · doi:10.1016/s0092-8674(01)00527-x · Cited by 2,659
Onufriev, A., Bashford, D., & Case, D. A. (2004) · Proteins: Structure, Function, and Bioinformatics · doi:10.1002/prot.20033 · Cited by 2,507
Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer
Minucci, S., & Pelicci, P. G. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1779 · Cited by 2,200
Negative Control of p53 by Sir2α Promotes Cell Survival under Stress
Luo, J., Nikolaev, A. Y., Imai, S.-I., Chen, D., Su, F., Shiloh, A., Guarente, L., & Gu, W. (2001) · Cell · doi:10.1016/s0092-8674(01)00524-4 · Cited by 2,081
Fraga, M. F., Ballestar, E., Villar-Garea, A., Boix-Chornet, M., Espada, J., Schotta, G., Bonaldi, T., Haydon, C., Ropero, S., Petrie, K., et al. (2005) · Nature Genetics · doi:10.1038/ng1531 · Cited by 1,923
Self-citationForce Fields for Protein Simulations
Ponder, J. W., & Case, D. A. (2003) · Advances in Protein Chemistry · doi:10.1016/s0065-3233(03)66002-x · Cited by 1,903
Histone deacetylase inhibitors: molecular mechanisms of action
Xu, W. S., Parmigiani, R. B., & Marks, P. A. (2007) · Oncogene · doi:10.1038/sj.onc.1210620 · Cited by 1,542
The Human Sir2 Ortholog, SIRT2, Is an NAD+-Dependent Tubulin Deacetylase
North, B. J., Marshall, B. L., Borra, M. T., Denu, J. M., & Verdin, E. (2003) · Molecular Cell · doi:10.1016/s1097-2765(03)00038-8 · Cited by 1,536
Marks, P. A., & Breslow, R. (2007) · Nature Biotechnology · doi:10.1038/nbt1272 · Cited by 1,196
Histone deacetylases and cancer
Glozak, M. A., & Seto, E. (2007) · Oncogene · doi:10.1038/sj.onc.1210610 · Cited by 1,031
p53 mutations in colorectal cancer.
Rodrigues, N. R., Rowan, A., Smith, M. E., Kerr, I. B., Bodmer, W. F., Gannon, J. V., & Lane, D. P. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.19.7555 · Cited by 1,003
Bitterman, K. J., Anderson, R. M., Cohen, H. Y., Latorre-Esteves, M., & Sinclair, D. A. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m205670200 · Cited by 1,002
Human SirT1 interacts with histone H1 and promotes formation of facultative heterochromatin.
Vaquero, A., Scher, M., Lee, D., Erdjument-Bromage, H., Tempst, P., & Reinberg, D. (2004) · Molecular Cell · doi:10.1016/j.molcel.2004.08.031 · Cited by 916
Calorie restriction–the SIR2 connection
Guarente, L., & Picard, F. (2005) · Cell · doi:10.1016/j.cell.2005.01.029 · Cited by 793
Epigenetics and aging: the targets and the marks
Fraga, M. F., & Esteller, M. (2007) · Trends in Genetics · doi:10.1016/j.tig.2007.05.008 · Cited by 690 · cited 1×
“Indeed, some targets, such as E2F transcription factor 1 and nuclear factor kappaB inhibitor, are important players in the apoptotic pathways (reviewed in Fraga and Esteller, 2007).”
BackgroundSelf-citationSirT2 is a histone deacetylase with preference for histone H4 Lys 16 during mitosis
Vaquero, A., Scher, M. B., Lee, D. H., Sutton, A., Cheng, H.-L., Alt, F. W., Serrano, L., Sternglanz, R., & Reinberg, D. (2006) · Genes & Development · doi:10.1101/gad.1412706 · Cited by 665
Tumor Suppressor HIC1 Directly Regulates SIRT1 to Modulate p53-Dependent DNA-Damage Responses
Chen, W. Y., Wang, D. H., Yen, R. C., Luo, J., Gu, W., & Baylin, S. B. (2005) · Cell · doi:10.1016/j.cell.2005.08.011 · Cited by 648
Sirtuins in aging and age-related disease
Longo, V. D., & Kennedy, B. K. (2006) · Cell · doi:10.1016/j.cell.2006.07.002 · Cited by 628
Discovery and development of SAHA as an anticancer agent
Marks, P. A. (2007) · Oncogene · doi:10.1038/sj.onc.1210204 · Cited by 626
Grozinger, C. M., Chao, E. D., Blackwell, H. E., Moazed, D., & Schreiber, S. L. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m106779200 · Cited by 539
Discovery of Indoles as Potent and Selective Inhibitors of the Deacetylase SIRT1
Napper, A. D., Hixon, J., McDonagh, T., Keavey, K., Pons, J.-F., Barker, J., Yau, W. T., Amouzegh, P., Flegg, A., Hamelin, E., et al. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm050522v · Cited by 523
Discovery, In Vivo Activity, and Mechanism of Action of a Small-Molecule p53 Activator
Lain, S., Hollick, J. J., Campbell, J., Staples, O. D., Higgins, M., Aoubala, M., McCarthy, A., Appleyard, V., Murray, K. E., Baker, L., et al. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.03.004 · Cited by 522
Antitumor Activity of a Small-Molecule Inhibitor of Human Silent Information Regulator 2 Enzymes
Heltweg, B., Gatbonton, T., Schuler, A. D., Posakony, J., Li, H., Goehle, S., Kollipara, R., DePinho, R. A., Gu, Y., Simon, J. A., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3617 · Cited by 469
Avalos, J. L., Bever, K. M., & Wolberger, C. (2005) · Molecular Cell · doi:10.1016/j.molcel.2005.02.022 · Cited by 464
Interactions between E2F1 and SirT1 regulate apoptotic response to DNA damage
Wang, C., Chen, L., Hou, X., Li, Z., Kabra, N., Ma, Y., Nemoto, S., Finkel, T., Gu, W., Cress, W. D., et al. (2006) · Nature Cell Biology · doi:10.1038/ncb1468 · Cited by 449
Ota, H., Tokunaga, E., Chang, K., Hikasa, M., Iijima, K., Eto, M., Kozaki, K., Akishita, M., Ouchi, Y., & Kaneki, M. (2006) · Oncogene · doi:10.1038/sj.onc.1209049 · Cited by 435
Inhibition of SIRT1 Reactivates Silenced Cancer Genes without Loss of Promoter DNA Hypermethylation
Pruitt, K., Zinn, R. L., Ohm, J. E., McGarvey, K. M., Kang, S.-H. L., Watkins, D. N., Herman, J. G., & Baylin, S. B. (2006) · PLoS Genetics · doi:10.1371/journal.pgen.0020040 · Cited by 387 · cited 6×
“In mammals, substrates for Sirt1 include histones (mainly lysine 16 of histone H4) (Vaquero et al., 2004; Pruitt et al., 2006), but also key transcription factors, such as p53 and forkhead transcriptional factors (reviewed in Fraga et al., 2007).”
BackgroundResultInfluentialStructure of the histone deacetylase SIRT2.
Finnin, M. S., Donigian, J. R., & Pavletich, N. P. (2001) · Nature Structural Biology · doi:10.1038/89668 · Cited by 385
Identification of a small molecule inhibitor of Sir2p
Bedalov, A., Gatbonton, T., Irvine, W. P., Gottschling, D. E., & Simon, J. A. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.261574398 · Cited by 346
Crystal Structure of a SIR2 Homolog–NAD Complex
Min, J., Landry, J., Sternglanz, R., & Xu, R.-M. (2001) · Cell · doi:10.1016/s0092-8674(01)00317-8 · Cited by 326
Cancer-Specific Functions of SIRT1 Enable Human Epithelial Cancer Cell Growth and Survival
Ford, J., Jiang, M., & Milner, J. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1923 · Cited by 298
Cross‐Talk between Aging and Cancer: The Epigenetic Language
FRAGA, M. F., AGRELO, R., & ESTELLER, M. (2007) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1395.005 · Cited by 251
Function of the SIRT1 protein deacetylase in cancer
Stünkel, W., Peh, B. K., Tan, Y. C., Nayagam, V. M., Wang, X., Salto‐Tellez, M., Ni, B., Entzeroth, M., & Wood, J. (2007) · Biotechnology Journal · doi:10.1002/biot.200700087 · Cited by 235
HDACs and HDAC inhibitors in colon cancer
Mariadason, J. M. (2008) · Epigenetics · doi:10.4161/epi.3.1.5736 · Cited by 222
Mai, A., Massa, S., Lavu, S., Pezzi, R., Simeoni, S., Ragno, R., Mariotti, F. R., Chiani, F., Camilloni, G., & Sinclair, D. A. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm050100l · Cited by 169
Self-citationParks, B. A., Jiang, L., Thomas, P. M., Wenger, C. D., Roth, M. J., Boyne, M. T., Burke, P. V., Kwast, K. E., & Kelleher, N. L. (2007) · Analytical Chemistry · doi:10.1021/ac070553t · Cited by 123
The Flavoring Agent Dihydrocoumarin Reverses Epigenetic Silencing and Inhibits Sirtuin Deacetylases
Olaharski, A. J., Rine, J., Marshall, B. L., Babiarz, J., Zhang, L., Verdin, E. M., & Smith, M. T. (2005) · PLoS Genetics · doi:10.1371/journal.pgen.0010077 · Cited by 99
Sun, Y., Sun, D., Li, F., Tian, L., Li, C., Li, L., Lin, R., & Wang, S. (2007) · Lung Cancer · doi:10.1016/j.lungcan.2007.05.013 · Cited by 73
Herranz, M., Martín‐Caballero, J., Fraga, M. F., Ruı́z-Cabello, J., Flores, J. M., Desco, M., Márquez, V. E., & Esteller, M. (2005) · Blood · doi:10.1182/blood-2005-05-2033 · Cited by 72
Self-citationSirT1 fails to affect p53‐mediated biological functions
Kamel, C., Abrol, M., Jardine, K. E., He, X., & McBurney, M. W. (2006) · Aging Cell · doi:10.1111/j.1474-9726.2006.00191.x · Cited by 71
Clark, A., Labute, P., & Santavy, M. (2006) · Journal of Chemical Information and Modeling · doi:10.1021/ci050550m · Cited by 55
Comparative and pharmacophore model for deacetylase SIRT1
Huhtiniemi, T., Wittekindt, C., Laitinen, T., Leppänen, J., Salminen, A., Poso, A., & Lahtela-Kakkonen, M. K. (2006) · Journal of Computer-Aided Molecular Design · doi:10.1007/s10822-006-9084-9 · Cited by 52
Analysis of Histone Modifications by Mass Spectrometry
Villar‐Garea, A., Israel, L., & Imhof, A. (2008) · Current Protocols in Protein Science · doi:10.1002/0471140864.ps1410s51 · Cited by 47
Self-citationTrastuzumab Plus Tamoxifen: Anti-Proliferative and Molecular Interactions in Breast Carcinoma
Ropero, S., Menéndez, J. A., Vázquez‐Martín, A., Montero, S., Cortés-Funes, H., & Colomer, R. (2004) · Breast Cancer Research and Treatment · doi:10.1023/b:brea.0000032981.20384.c6 · Cited by 47
Self-citation
Cited by
Mammalian Sirtuins: Biological Insights and Disease Relevance
Haigis, M. C., & Sinclair, D. A. (2010) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev.pathol.4.110807.092250 · Cited by 2,085
Cancer epigenetics reaches mainstream oncology
Rodríguez-Paredes, M., & Esteller, M. (2011) · Nature Medicine · doi:10.1038/nm.2305 · Cited by 1,205
Self-citationThe sirtuin family in health and disease
Wu, Q.-J., Zhang, T.-N., Chen, H.-H., Yu, X.-F., Lv, J.-L., Liu, Y.-Y., Liu, Y.-S., Zheng, G., Zhao, J.-Q., Wei, Y.-F., et al. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01257-8 · Cited by 862
SIRT Inhibitors Induce Cell Death and p53 Acetylation through Targeting Both SIRT1 and SIRT2
Peck, B., Chen, C.-Y., Ho, K.-K., Di Fruscia, P., Myatt, S. S., Coombes, R. C., Fuchter, M. J., Hsiao, C.-D., & Lam, E. W.-F. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0971 · Cited by 433
Acetylation stabilizes ATP-citrate lyase to promote lipid biosynthesis and tumor growth
Lin, R., Tao, R., Gao, X., Li, T., Zhou, X., Guan, K.-L., Xiong, Y., & Lei, Q.-Y. (2013) · Molecular Cell · doi:10.1016/j.molcel.2013.07.002 · Cited by 384
Metadata
- Authors
- Lara, E., Mai, A., Calvanese, V, Altucci, L., Lopez-Nieva, P., Martinez-Chantar, M. L., Varela-Rey, M., Rotili, D., Nebbioso, A., Ropero, S., Montoya, G., Oyarzabal, J., Velasco, S., Serrano, M., Witt, M., Villar-Garea, A., Inhof, A., Mato, J. M., Esteller, M., & Fraga, M. F.
- Venue
- Oncogene
- Published
- 2008-12-08
- Volume
- 28
- Issue
- 6
- Pages
- 781-791
- ISSN
- 0950-9232 (ISSN-L)
- 1476-5594
- OpenAlex
- W2089112805
- Cited by
- 259
- References
- 46
- FWCI
- 7.08
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.